Effects of imipenem-cilastatin sodium combined with immunoglobulin on serum PCT, hs-CRP and TNF-α in children with baby sepsis complicated with disseminated intravascular coagulation / 中国临床药理学与治疗学

ABSTRACT

AIM: To investigate the effects of imipenem-cilastatin sodium combined with immunoglobulin on serum PCT, hs-CRP and TNF-α in child with baby sepsis complicated with disseminated intravascular coagulation (DIC). METHODS: Ninty-two cases of patients with sepsis and DIC neonates admitted to our hospital from January 2013 to April 2019 were enrolled in this study. All the children were divided into observation group and control group according to random number table method, 46 cases in each group. The patients in the control group were treated with imipenem-cilastatin sodium, and the patients in the observation group were treated with imipenem-cilastatin sodium combined with immunoglobulin. The efficacy of the two groups, the time of DIC index returned to normal, bleeding stopped and ICU hospitalization time, coagulation parameters (FIB, PLT, D-D, TT), serum inflammatory factor levels and incidence of adverse reactions were compared. RESULTS: The total effective rate of treatment in the observation group was 93.48% (43/46), which was higher than that in the control group (78.26%, 36/46) (P0.05). CONCLUSION: Imipenem-cilastatin combined with immunoglobulin is effective in the treatment of baby sepsis complicated with DIC. It can alleviate or eliminate bleeding and other symptoms, shorten ICU hospitalization time, improve coagulation function, and reduce serum PCT and hs-CRP, TNF-α expression, and the body's inflammatory response, combined with fewer adverse reactions, which has a higher clinical value.